Nirrin Technologies Launches Atlas for At-line Analysis at the Point of Sampling
09 July 2024 - 2:00PM
Business Wire
Atlas delivers critical data on buffer
components and product titer in one minute at the point of
sampling, giving biopharma quantitative, actionable data to take
control of their bioprocesses
Nirrin Technologies, a developer of analytical tools poised to
transform bioprocess analysis, today announced the launch of their
Atlas™ system for at-line excipient and product titer quantitation
in downstream bioprocessing applications.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240709374664/en/
Nirrin Technologies' Atlas system
delivers critical data on buffer components and product titer in
one minute at the point of sampling, giving biopharma quantitative,
actionable data to take control of their bioprocesses (Photo:
Business Wire)
The existing analytical workflow for biomanufacturing is full of
blind spots and bottlenecks that contribute to increased time to
market and manufacturing costs for critical drugs. Therapeutic
development is an iterative and complicated process requiring
analysis at each step of the process and suffers from either no
data or slow data collection. If samples are taken, they are
typically sent to a core analytical lab for HPLC analysis, and drug
development timelines are often delayed for 4-6 weeks waiting on
its retrospective data.
Powered by Nirrin’s proprietary high-precision tunable laser
spectroscopy™ (HPTLS) technology, Atlas enables simultaneous
analysis of buffer excipients, such as surfactants and amino acids,
and high concentration proteins, such as monoclonal antibodies,
peptides and vaccines in one minute throughout the bioprocess. This
easy-to-use system delivers critical data with the accuracy and
sensitivity of HPLC — bringing the power of the core lab right to
the point of sampling. Atlas quickly reveals blind spots and
overlooked issues that can become bigger problems throughout the
bioprocess, giving scientists more predictive and proactive control
over their process like never before. Armed with the needed
insights to make confident decisions in-hand, they can eliminate
unnecessary wait time and be more selective on which samples are
sent to the core lab for further analysis.
Early adopter studies conducted by ten top global pharmaceutical
companies demonstrated the potential of Atlas’s HPTLS as a reliable
method that overcomes the limitations of traditional analysis
techniques and opens new possibilities for studying and optimizing
protein formulations.
Nirrin’s HPTLS technology unlocks the power of near-infrared
(NIR) spectroscopy with a tunable laser source to provide unique,
quantitative signatures for excipients, proteins, surfactants and
more. “Bioprocess groups shouldn’t have to wait for retrospective
data from the core lab, they need data they can trust, now,” said
Bryan Hassell, Ph.D., Nirrin Founder and CTO. “Atlas debottlenecks
current analytical workflows with a system anyone can use and get
accurate, reliable data in a minute or less. There aren’t any other
at-line technologies that can provide the data-driven insights
biopharma needs to react quickly and effectively.”
“With Atlas, bioprocess groups now have a single tool that can
be used to benchmark their unique processes in both development and
manufacturing, and deliver cost-effective, actionable answers
on-demand,” said Greg Crescenzi, CEO of Nirrin. “Atlas is Nirrin’s
first step towards what the biopharmaceutical industry has been
waiting on for a long time — real-time monitoring and integrated
control of their bioprocess. Our current development focus is on
continuous manufacturing, and early collaborators are already
having great success with Atlas for analysis of their critical
process parameters.”
Atlas shipments begin in early July. Learn more at
https://www.nirrin.tech/atlas/, or visit Nirrin at BioProcess
International September 23-26. To get your own hands-on experience
with Atlas, contact our team for an evaluation.
About Nirrin Technologies
We are transforming bioprocess analytics with our high-precision
tunable laser spectroscopy platform (HPTLS). Our Atlas™ system
provides a process analytical solution for complex biologics and
advanced therapies to reduce development costs and speed time to
market. Fingerprinting bioprocesses in real time, Atlas enables
insights on product titer and buffer/excipient concentrations
at-line, in-line, and in-situ in minutes — delivering improved
process control, faster process development, and advanced
manufacturing.
For more information, visit nirrin.tech.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240709374664/en/
Media: Alyssa Ludvino Director of Marcom
alyssa@nirrin.tech